Atlas Trials

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Clinical trial NCT03495323 · COMPLETED

Trial details

NCT number
NCT03495323
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer
Start date
2018-05-16
Primary completion
2021-02-01
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.